J. Folkman and Y. Shing, “Angiogenesis”, The Journal of Biological Chemistry, vol. 267, No. 16, (Jun. 5, 1992), pp. 10931-10934. |
J. Folkman and M. Klagsbrun, “Angiogenic Factors”, Science, vol. 235 (Jan. 23, 1987), pp. 442-447. |
J. Folkman, “How is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?—G.H.A. Clowes Memorial Award Lecture”, Cancer Research, vol. 46 (Feb. 1986), pp. 467-473. |
J. Folkman, “What Is The Evidence That Tumors Are Angiogenesis Dependent?”, Journal of the National Cancer Institute, vol. 82, No. 1 (Jan. 3, 1990), pp. 4-6. |
N. Weidner, M.D., et al., “Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma”, The New England Journal of Medicine, vol. 324 (Jan. 3, 1991), pp. 1-8. |
D. Ingber, et al., “Synthetic Analogues of Fumagillin Covalently Binds and Inhibits The Tumour Growth”, Letters to Nature, vol. 348, (Jun. 12, 1990), pp. 555-557. |
N. Sin, et al., “The Anti-Angiogenic Agent Fumagillin Covalently Binds and Inhibits The Methionine Aminopeptidase, MetAP-2”, Proc. Natl. Acad. Sci. USA, vol. 94 (Jun. 1997), pp. 6099-6103. |
E.C. Griffith, et al., “Methionine Aminopeptidase (type 2) Is the Common Target For Angiogenesis Inhibitors AGM-140 And Ovalicin”, Chemistry and Biology, vol. 4 (Jun. 1997), pp. 461-471. |
J. Abe, et al., “A Fumagillin Derivative Angiogenesis Inhibitor, AGM-1470, Inhibits Activation of Cyclin-dependent Kinases and Phosphorylation of Retinoblastoma Gene Product but not Protein Tyrosyl Phosphorylation of Protooncogene Expression in Vascular Endothelial Cells”, Cancer Research, vol. 54 (Jul. 1, 1994), pp. 3407-3412. |
Nishizawa, R., “Synthesis and Structure-Activity Relationships of Bestatin Analogues, Inhibitors of Aminopeptidase B”, Journal of Medicinal Chemistry, US, American Chemical Society, vol. 20, No. 4, (1977), pp. 510-515. |